Table II.
Correlation between miR-320a expression and clinicopathological characteristics in invasive breast cancer (n=130).
| miR-320a expression | |||
|---|---|---|---|
|
|
|||
| Characteristics | High expression, n (%) | Low expression, n (%) | P-value |
| Age (years) | 0.164 | ||
| <45 | 9 (60) | 6 (40) | |
| 45–55 | 23 (38) | 38 (62) | |
| >55 | 28 (52) | 26 (48) | |
| Tumor size (cm) | 0.046 | ||
| ≤2.5 | 42 (53) | 37 (47) | |
| >2.5 | 18 (35) | 33 (65) | |
| Lymph node metastasis | <0.001 | ||
| 0 | 46 (65) | 25 (35) | |
| 1–2 | 10 (31) | 22 (69) | |
| >2 | 4 (15) | 23 (85) | |
| Distant metastasis | 0.006 | ||
| No | 59 (50) | 59 (50) | |
| Yes | 1 (8.3) | 11 (91.7) | |
| Histological grade | 0.745 | ||
| Low (I) | 7 (50) | 7 (50) | |
| Intermediate (II) | 44 (47) | 49 (53) | |
| High (III) | 9 (39) | 14 (61) | |
| Clinical TNM stage | <0.001 | ||
| I | 28 (64) | 16 (36) | |
| II | 27 (50) | 27 (50) | |
| III–IV | 5 (16) | 27 (84) | |
| Estrogen receptor | 0.684 | ||
| − | 27 (44) | 34 (56) | |
| + | 33 (48) | 36 (52) | |
| Progesterone receptor | 0.352 | ||
| − | 32 (43) | 43 (57) | |
| + | 28 (51) | 27 (49) | |
| HER-2 expression | 0.290 | ||
| − | 26 (52) | 24 (48) | |
| + | 34 (42.5) | 46 (57.5) | |
| Menopause | 0.697 | ||
| No | 22 (44) | 28 (56) | |
| Yes | 38 (47.5) | 42 (52.5) | |
TNM, tumor lymph-node metastasis; HER-2, human epidermal growth factor-2.